JMP Securities Boosts Nevro (NYSE:NVRO) Price Target to $115.00
Nevro (NYSE:NVRO) had its price objective boosted by JMP Securities to $115.00 in a report released on Thursday morning, The Fly reports. The firm currently has an outperform rating on the medical equipment provider’s stock.
NVRO has been the topic of several other research reports. Oppenheimer assumed coverage on Nevro in a research report on Tuesday, October 22nd. They issued a market perform rating on the stock. Canaccord Genuity upped their price objective on Nevro from $50.00 to $59.00 and gave the stock a hold rating in a research report on Friday, August 9th. Leerink Swann set a $98.00 price objective on Nevro and gave the stock a buy rating in a research report on Friday, August 23rd. Bank of America upped their price objective on Nevro from $70.00 to $74.00 and gave the stock a buy rating in a research report on Friday, August 9th. Finally, ValuEngine downgraded Nevro from a buy rating to a hold rating in a research note on Wednesday, October 2nd. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and seven have issued a buy rating to the stock. The company has a consensus rating of Hold and an average target price of $86.83.
Nevro stock traded up $2.21 during mid-day trading on Thursday, hitting $105.59. The company had a trading volume of 798,622 shares, compared to its average volume of 519,500. The company has a current ratio of 6.05, a quick ratio of 4.66 and a debt-to-equity ratio of 0.89. Nevro has a 12-month low of $34.75 and a 12-month high of $108.20. The company’s fifty day moving average is $85.49 and its 200-day moving average is $72.60. The company has a market capitalization of $2.69 billion, a price-to-earnings ratio of -64.38 and a beta of 0.21.
In other news, VP Doug Alleavitch sold 1,000 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $100.00, for a total transaction of $100,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 7.60% of the company’s stock.
Several hedge funds have recently made changes to their positions in NVRO. Invesco Ltd. raised its stake in shares of Nevro by 316.2% during the 2nd quarter. Invesco Ltd. now owns 1,970,969 shares of the medical equipment provider’s stock worth $127,778,000 after buying an additional 1,497,455 shares during the period. Price T Rowe Associates Inc. MD raised its stake in shares of Nevro by 91.5% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 3,078,635 shares of the medical equipment provider’s stock worth $199,588,000 after buying an additional 1,470,807 shares during the period. Perceptive Advisors LLC raised its stake in shares of Nevro by 172.9% during the 2nd quarter. Perceptive Advisors LLC now owns 1,137,765 shares of the medical equipment provider’s stock worth $73,761,000 after buying an additional 720,816 shares during the period. Nuveen Asset Management LLC acquired a new position in shares of Nevro during the 2nd quarter worth approximately $26,818,000. Finally, D. E. Shaw & Co. Inc. raised its stake in shares of Nevro by 11.7% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 2,067,400 shares of the medical equipment provider’s stock worth $134,029,000 after buying an additional 216,680 shares during the period.
Nevro Company Profile
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.
See Also: Technical Analysis
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.